Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2022 | ADCs in lymphoma

Stephen Ansell • 4 Jun 2022
ASCO 2022
Hodgkin Lymphoma Lymphoma Antibodies CAR-T

Stephen M. Ansell, MD, PhD, Mayo Clinic, Rochester, MN, gives his highlights from the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, emphasizing the promise of antibody-drug conjugates (ADCs) in lymphoma which represent a new frontier in oncology. This interview took place at the ASCO 2022 Annual Meeting in Chicago, IL.

More from Stephen Ansell

Mantle cell lymphoma: frontline therapy, the role of autoSCT, the value of MRD, & more 15:05
Mantle cell lymphoma: frontline therapy, the role of autoSCT, the value of MRD, & more
Michael Wang et al. • 27 Sep 2025
How the Hodgkin lymphoma treatment landscape is evolving & future directions 1:09
How the Hodgkin lymphoma treatment landscape is evolving & future directions
Stephen Ansell • 19 Jun 2025
Exploring the combination of brentuximab vedotin & nivolumab in older patients with Hodgkin lymphoma 1:12
Exploring the combination of brentuximab vedotin & nivolumab in older patients with Hodgkin lymphoma
Stephen Ansell • 19 Jun 2025
Challenges that remain in treating older patients with Hodgkin lymphoma 0:54
Challenges that remain in treating older patients with Hodgkin lymphoma
Stephen Ansell • 19 Jun 2025

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals